Preferred Label : AC Followed by Pertuzumab/Trastuzumab/Docetaxel Regimen;
NCIt synonyms : Doxorubicin/Cyclophosphamide Followed by Pertuzumab Trastuzumab Docetaxel; AC Followed by Docetaxel Trastuzumab Pertuzumab; AC Followed by Pertuzumab-Trastuzumab-Docetaxel Regimen; AC Followed by Docetaxel Pertuzumab Trastuzumab; Doxorubicin/Cyclophosphamide Followed by Pertuzumab/Trastuzumab/Docetaxel; AC-Pertuzumab Trastuzumab Docetaxel; AC Followed by Pertuzumab Trastuzumab Docetaxel;
NCIt related terms : AC-THP (Docetaxel); AC-THP (Docetaxel) (trastuzumab-anns); AC-THP (Docetaxel) (trastuzumab-zerc); AC-THP (Docetaxel) (trastuzumab-dttb); AC-THP (Docetaxel) (trastuzumab-qyyp); AC-THP (Docetaxel) (trastuzumab-dkst); AC-THP (Docetaxel) (trastuzumab-pkrb); AC-THP (Docetaxel) (trastuzumab-herw); AC-THP (Docetaxel) (trastuzumab-strf);
NCIt definition : A regimen consisting of cyclophosphamide and doxorubicin followed by pertuzumab, trastuzumab,
and docetaxel, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive
breast cancer.;
NCIt note : Source: NCCN Guidelines 2017;
NCI Metathesaurus CUI : CL525006;
Codes from synonyms : 37438; 128917; 129402; 129305; 129208; 128820; 129111; 129014; 139590;
Origin ID : C138031;
UMLS CUI : C4527339;
Semantic type(s)
- chemotherapy_regimen_has_component
- concept_is_in_subset
